Table 3

P values for subgroup difference for ΔDAS28(CRP), final DAS28(CRP), good EULAR response and non-EULAR response between TNFi and placebo

	Studies (n)	P value for subgroup difference
	Studies (n)	ΔDAS28(CRP)	DAS28(CRP) final	Good EULAR response	EULAR non-response
Smoking
Yes	14	0.87	0.77	0.95	0.97
No	14	0.87	0.77	0.95	0.97
Physical activity
Yes	5	0.81	0.58	0.87	0.95
No	5	0.81	0.58	0.87	0.95
Sex
Women	27	0.34	0.64	0.50	0.94
Men	27	0.34	0.64	0.50	0.94
Age (years)
>50 years	27	0.08	0.15	0.59	0.34
≤50 years	27	0.08	0.15	0.59	0.34
BMI (kg/cm²)
≥30	28	0.20	0.12	0.22	0.01
<30	28	0.20	0.12	0.22	0.01
RF status
Positive	28	0.12	0.28	0.61	0.13
Negative	28	0.12	0.28	0.61	0.13
ACPA status
Positive	13	0.62	0.99	0.79	0.29
Negative	13	0.62	0.99	0.79	0.29
Disease duration (years)
<2	22	0.25	0.07	0.69	0.33
2–
≥10
Baseline DAS28
>5.1	27	0.27	0.44	0.73	0.31
≤5.1	27	0.27	0.44	0.73	0.31

ACPA, anticitrullinated protein antibody; BMI, body mass index; CRP, C reactive protein; Baseline DAS28, DAS28(CRP) score at baseline; DAS28, Disease Activity Score on 28 joints; ΔDAS28(CRP), DAS28(CRP) change; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitors.